Revance Receives FDA Acceptance of BLA Resubmission for DaxibotulinumtoxinA for Glabellar Lines

Revance Therapeutics, Inc. RVNC announced acceptance of Biologics License Application (BLA) by the U.S. Food and Drug Administration (FDA) of its drug candidate DaxibotulinumtoxinA for Injection for the treatment of patients with moderate to severe glabellar lines. The regulatory agency has set a target action date of September 8, 2022.

The FDA designated the BLA as a Class 2 resubmission, which has a six-month review period and includes a required reinspection of the company's manufacturing facility.

The resubmission was followed by the Type A meeting in December 2021.

Revance Therapeutics shares trading down 3 percent at $16.89 during after hours.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareSmall CapFDAGeneral
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!